Clinical Trials Logo
  1. Home
  2. Cancer
  3. NCT06367959
  4. Details
NCT06367959 Clinical Trial

Health Benefits of Writing Therapy Among Asian American Cancer Survivors

Cancer Clinical Trial

Official title:
Health Benefits of Writing Therapy Among Asian American Cancer Survivors

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06367959
Other study ID # 2021-0324
Secondary ID NCI-2024-02939
Status Recruiting
Phase N/A
First received
Last updated
Start date July 27, 2023
Est. completion date August 31, 2026

Study information
Verified date April 2024
Source M.D. Anderson Cancer Center
Contact Qian Lu, MD, PHD
Phone (713) 745-8324
Email qlu@mdanderson.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To learn more about participant experience as a Asian American immigrant breast cancer survivor and how writing about participant experiences may affect participant's health.

Description:

Primary Objective: To determine the effects of writing therapy on QOL and perceived stress at the 6- and 12-month follow-ups. Secondary Objective: To discover the effects of writing therapy on stress biomarkers and perceived stress at the 3-month follow-up. To explore the psychosocial and cultural mechanisms responsible for the benefits of writing therapy by using mixed methods.

Recruitment information / eligibility
Status Recruiting
Enrollment 192
Est. completion date August 31, 2026
Est. primary completion date August 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult (aged 18 and older) diagnosed with stage 0-III cancer (or acute leukemia in remission/ chronic myeloid leukemia in chronic phase). - Self-identified as Asian, Asian Americans, any Asian or Asian American subgroup (Chinese, Vietnamese, Indian, Korean, etc.) ethnic/cultural background - Completed primary treatment, including surgery, chemotherapy, and/or radiation therapy, immunotherapy, or targeted therapy within the preceding 5 years. - Comfortable reading in English or in Chinese. Exclusion Criteria: - Inability to provide informed consent.

Study Design

Related Conditions & MeSH terms

Intervention

Behavioral:
• Esays
Participants will write about their experiences One (1) time each week for 3 weeks at the beginning of the study and then 1 more time 9 months later. Participants will be asked to write about their experiences with cancer in English or Chinese and to write as much as they can for about 20-30 minutes for each essay.
• Questionnaires
Participants will answer a questionnaire at the beginning of the study and then 3, 6, and 12 months later. Participants will also answer a questionnaire about their thoughts on writing and on the study after they complete the third essay.

Locations
Country Name City State
United States MD Anderson Cancer Center Houston Texas

Sponsors (1)
Lead Sponsor Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Primary Outcome Measure: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 Time Frame: through study completion; an average of 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases

External Links